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Agenda
Unlocking the
Knowledge

The key to delivering the compliance and business benefits
outlined in ICH Q10

Nuala Calnan
PhD Researcher
Pharmaceutical Science & Regulatory Team (PSRT)
School of Chemical & Pharmaceutical Sciences
Dublin Institute of Technology
Ireland

PSRT Research Program
Aim: The purpose of this research is to develop a
science and risk based methodology for use by the
Pharmaceutical Industry which will provide a
practical integrated knowledge framework for
achieving, maintaining and facilitating continual
improvement of the ‘State of Control’ across the
entire lifecycle relating to the commercial
manufacture of human drug products.
An associated implementation toolset based on
lean/six sigma principles will also be developed

Introduction to the Research program
Overview of the Regulatory Drivers
Review of Recent Regulatory Actions
Challenges of delivering a holistic approach to the
Pharmaceutical Quality System (Q10) expectations
• Review of key relevant findings of recent ‘Operational
Excellence in the Pharmaceutical Industry’ St. Gallen Uni.
benchmarking report
• Knowledge is the Key
• How can we utilise familiar OPEX, Lean/ Six Sigma tools to
capture this knowledge and deliver the expectations and
opportunities for ICH Q10
•
•
•
•

George Nelson ball clock

Where were you in July 2003 ?
What were the key regulatory
strategies in use in your organisation at
that time?
Was your organization introducing new
products into your manufacturing
facilities ?
Preparing for a regulatory inspection?
Perhaps even busy responding to
regulatory observations or
actions following a recent inspection
or audit?
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Quality: A New Paradigm*
In July 2003, at an
important ICH meeting in
Brussels, a new quality
vision was agreed on. This
emphasized a risk and
science-based approach to
pharmaceuticals in an
adequately implemented
quality system.
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ICH Q10 Pharmaceutical Quality System
Pharmaceutical
Development

Technology
Transfer

Investigational products
Nov 2005 & Nov 2008

Commercial
Manufacturing

Discontinuation

GMP

Management Responsibilities
PQS
elements

Enablers

Process Performance & Product Quality Monitoring System
Corrective Action / Preventive Action (CAPA) System
Change Management System
Management Review
Knowledge Management
Quality Risk Management
Source: ICH, November 2010

*This vision was referred to by Jean Louis Robert (ICH Q-IWG Rapporteur) as ‘Quality: A New Paradigm’ in the Integrated Implementation Training Workshop materials delivered in
Washington DC in November 2010.

ICH Q10 PQS – Regulatory Context
Take note…
• Much of the content of ICH Q10 applicable to manufacturing sites is
currently specified by regional GMP requirements.
• ICH Q10 is not intended to create any new expectations beyond current
regulatory requirements.
• Consequently, the content of ICH Q10 that is additional to current regional
GMP requirements is optional.
However,
• ICH Q10 demonstrates industry and regulatory authorities’ support of an
effective pharmaceutical quality system to enhance the quality and
availability of medicines around the world in the interest of public health.

Recent Regulatory Action example 1
FDA Warning Letter to a Danish
Firm dated 2nd May 2012
Failure to establish and maintain adequate
procedures for validating the device
design. Design validation shall include risk
analysis, where appropriate, as required by
21 CFR 820.30(g).
For example, your firm’s procedure, (b)(4),
dated 01/10/2011, does not include or refer
to the process to be used when conducting a
risk analysis. ...... your firm did not establish
a process for identifying the potential
hazards of the design project as required by
the standard being used (b)(4).

• Implementation of ICH Q10 throughout the product lifecycle should
facilitate innovation and continual improvement and strengthen the link
between pharmaceutical development and manufacturing activities
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Recent Regulatory Action example 2
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Recent Regulatory Action example 3
FDA Warning Letter to a US OTC
Manufacturer dated….2011

FDA Warning Letter to a Spanish
Firm dated 24th April 2012

Warning Letter OTC Manufacturer
• Firm’s management, including the Quality Control
Unit, was not responsive to adverse trend of
customer complaints.
• Failure of your Quality Control Unit to ensure a
thorough investigation with conclusions and follow up
accomplished (two deviations, both 211.192 and
211.198)
• Senior management (includes corporate in this case)
is responsible for ensuring the quality, safety, and
integrity of your firm’s drug products.

3. Your firm has not established scientifically
sound and appropriate specifications,
standards, sampling plans, and test
procedures designed to assure that
drug products conform to appropriate
standards of identity, strength,
quality, and purity [21 C.F.R. § 211.160(b)].

Source: CDER Update University of Georgia GMP Conference March 15-17, 2011, Richard L. Friedman, Director, Division of Manufacturing and Product Quality, Office of Compliance
FDA/CDER

Challenges to Holistic Implementation of QbD Principles

St.Gallen University OPEX Benchmarking
Industry

Pharmaceutical

Number of
Production Sites

181 (Total)
134 (Formulation & Packaging)
38 (API)
9 (Biotech)

Number of
Companies

91 (Total)
including ten companies of the Top
20*

Content – Scope

Enabler Implementation and
Performance Metrics (KPIs)

Content – Modules

Total Productive Maintenance (TPM)
Total Quality Management (TQM)
Just-in-Time (JIT)
Effective Management System

Status: November 2011

*according to Pharmaceutical Executive

Published 2010,
Foreword written by ISPE
Operations Management COP
Source: Mastering Plant Complexity and the Impact of Operational Excellence, Prof. Dr. Thomas Friedli, University of St.Gallen, OPEX-Benchmarking
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How to achieve Excellence?
Excellence deals with doing the right things (quality, delivery) and
doing things right (efficiency, costs)
1 Measure and control the whole picture!
Total Productive
Maintenance
Capacity and Technology
Management
Preventive Maintenance
Integration of operators?
Prefer external or internal
maintenance?

Technology Assessment and
Usage
Role of leading edge
technology?
Equipment is protected by
patent?

Housekeeping

Total Quality
M anagement
Quality and Process
Management
Process Management
Statistical process control and
process quality?
Role of PAT implementation

Customer Integration
Collaboration with R&D to
accelerate scale-ups?
Standardized procedures for
process and product transfer?

Supplier Quality Management

Cleaning by operators?

Joint initiatives?
Feedback survey?

OEE (A PI)
Average Sample
Top Performer
Lowest 10%

71,6%
95,0%
60,5%

Materials and Operations
Management
Planning Adherence

Pull Production
Make-to-forecast or make-toorder?
Kanban systems?

Layout Optimization
Design by product groups?
Tact time, continuous flow?

Top Performer
Lowest 10%

What does Top Performance mean for TQM?

A Top Performer has a
higher yield and a
comparable low cost of
quality

Setup Time Reduction
Priority of setup time
reduction?

73,2%
95,0%
61,5%

Average Sample
Top Performer
Lowest 10%

96,6%
99,0%
94,5%

Lowest 10%

Deviations

85,0%
32,9%

…

…

…

Average Sample
Top Performer
Lowest 10%

Source: Mastering Plant Complexity and the Impact of Operational Excellence, Prof. Dr. Thomas Friedli, University of St.Gallen, OPEX-Benchmarking

Average Sample
1,6%
Top Performer 0,5%
Lowest 10%
2,3%

Quality Cost
(direct Empl.) [in €]

Rejected Batches
Average Sample 0,93%
Top Performer 0,05%
Lowest 10%
2,60%

51,0%

Top Performer

Complaint Rate Customer

Yield

Functional Integration
Average Sample

c u -tr a c k

Results from 2011 (based on 2010 data)

The Top 10% of our
sample have a
QA&QC/directEmployees-ratio of 22%
compared to this Top
Performer´s ratio of 8.5%

Smoothly leveled production
or high level of capacity
utilization?

Forecast Accur acy
Average Sample

2 Stabilize first, reduce waste second!

Just-I n-Time
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28,8
10,0
84,5

Average Sample
Top Performer
Lowest 10%

24.456
18.871
16.030

QA&QC/direct
Employees
35,3%
Average Sample
Top Performer 8,5%
Lowest 10%
30,6%

Source: Mastering Plant Complexity and the Impact of Operational Excellence, Prof. Dr. Thomas Friedli, University of St.Gallen, OPEX-Benchmarking

Acknowledgement
Special thanks to
Dr. Thomas Friedli
who generously
shared his June
2012 presentation

Vol 32, Number 4
Jul / Aug 2012
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Unlocking the Knowledge
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Knowledge Creation- Ikujiro Nonaka
“Knowledge is dynamic, since it is
created in social interactions amongst
individuals and organisations”
“Without real exchange, you can’t
create knowledge. Knowledge creation
is a human activity.”

Unlocking the tacit knowledge
within our organisations will be one of the
significant factors to successful
implementation
of effective and efficient
Pharmaceutical Quality Systems

“Tacit knowledge is a key
component of innovation”

Source : SECI, Ba and Leadership: a Unified Model of Dynamic Knowledge Creation Ikujiro Nonaka, Ryoko Toyama and Noboru Konno, Long Range
Planning 33 (2000) 5±34

Data to Wisdom -DIKW Model

Path Forward for Implementation
The Challenge
How can we build
Knowledge Networks
utilising familiar OPEX, Lean/ Six
Sigma tools to capture key
Tacit Knowledge
and manage the delivery of
Process Wisdom
to enhance
Quality Decision Making
meeting the expectations and
opportunities of ICH Q10 ?

Fourth Generation R&D: Managing Knowledge, Technology and Innovation, W.L. Miller and L. Morris, John
Wiley & Sons, 1999. p 87.
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Currently Developing a Pharma
Lean Six Sigma Toolset
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Go Raibh Maith Agat
Thank You

Deming’s System of Profound Knowledge
Deming advocated that all managers need to have
what he called a System of Profound Knowledge,
consisting of four parts:

Some extra bits!

• Appreciation of a system: understanding the
overall processes involving suppliers, producers,
and customers (or recipients) of goods and
services
• Knowledge of variation: understanding the
range and causes of variation in quality
• Theory of knowledge: the concepts explaining
knowledge and the limits of what can be known
• Knowledge of psychology: understanding the
concepts of human nature.
Source: ISPE C&Q Seminar June 2008 Washington- Good Engineering Practice, Nuala Calnan
24
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Deming's 14 key principles for
transforming business effectiveness
from Out of the Crisis (1992)
1. Create constancy of purpose toward
improvement.
2. Adopt the new philosophy and take
on leadership for change.
3. Cease dependence on inspection to
achieve quality by building quality
into the product in the first place.
4. End the practice of awarding business
on the basis of price tag.
5. Improve constantly and thus
constantly decrease cost
6. Institute training on the job.
7. Institute leadership.
8. Drive out fear
9. Break down barriers between
departments
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Some Useful References

10. Eliminate slogans, as the bulk of the
causes of low quality belong to the
system and not the work force.
11. a. Eliminate work standards (quotas).
Substitute leadership.
b. Eliminate management by objective.
Substitute leadership.
12. a. Remove barriers that rob the worker
of his right to pride of workmanship.
b. Remove barriers that rob people in
management and in engineering of their
right to pride of workmanship.
13. Institute a vigorous program of

• O’Donnell, K., Strategies for Addressing the Problems of Subjectivity and
Uncertainty in Quality Risk Management Exercises: Part I — The Role of
Human Heuristics, Journal of Validation Technology, Vol. 16, No. 3,
Summer 2010
• O’Donnell, K., Strategies for Addressing the Problems of Subjectivity and
Uncertainty in Quality Risk Management Exercises: Part II — Risk
Communication and Perception, Journal of Validation Technology, Vol. 16,
No. 4, Autumn 2010

education and self-improvement.

14. Put everybody in the company to work
to accomplish the transformation. The

transformation is everybody's work.

Source: ISPE C&Q Seminar June 2008 Washington- Good Engineering Practice, Nuala Calnan
25
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